Obligatory Post-Registration Open-Label, Non-Comparative Multicenter Study of Efficacy and Tolerance Rate of Caelyx [pegylated liposomal doxorubicin hydrochloride] as Monotherapy in Patients With Epithelial Ovarian Cancer, Resistant to Previous Platinum Therapy

Trial Profile

Obligatory Post-Registration Open-Label, Non-Comparative Multicenter Study of Efficacy and Tolerance Rate of Caelyx [pegylated liposomal doxorubicin hydrochloride] as Monotherapy in Patients With Epithelial Ovarian Cancer, Resistant to Previous Platinum Therapy

Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Jun 2017

At a glance

  • Drugs Doxorubicin liposomal (Primary)
  • Indications Ovarian cancer
  • Focus Therapeutic Use
  • Sponsors Schering-Plough
  • Most Recent Events

    • 25 Aug 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top